Bevacizumab and AZD2171 in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma - Related Studies

Bevacizumab and AZD2171 in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma

This study is currently recruiting participants.

Study NCT00458731. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Lymphoma
		Small Intestine Cancer

2	Additional conditions recognized in this trial
		Duodenal Neoplasms
		Ileal Neoplasms
		Intestinal Neoplasms
		Jejunal Neoplasms
		Lymphoma, Non-Hodgkin

3	More general conditions related to this trial
		Digestive System Diseases
		Digestive System Neoplasms
		Duodenal Diseases
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Ileal Diseases
		Immune System Diseases
		Immunoproliferative Disorders
		Intestinal Diseases
		Jejunal Diseases
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site

4	Interventions listed in this trial
		bevacizumab
		cediranib
		biopsy
		flow cytometry
		fluorescent antibody technique
		laboratory biomarker analysis
		pharmacological study

5	More general drug interventions related to this trial
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Antineoplastic Agents
		Growth Inhibitors
		Growth Substances
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

6	Sponsors listed in this trial
		M.D. Anderson Cancer Center
		National Cancer Institute (NCI)